Diabetes Forecast releases 2011 consumer guide
NEW YORK — The magazine of the American Diabetes Association has released its annual consumer guide in its January issue.
Diabetes Forecast highlighted what’s new and on the horizon for the six categories of diabetes-management products, including blood-glucose meters and insulin pens and pumps, as well as diabetes drugs available in the United States, ranked by type and popularity. The guide also spotlighted mobile applications and what devices they can be used for.
The magazine publishes the guide to help diabetics select products that best meet their needs, the American Diabetes Association said.
Click here to read the full guide.
Pfizer inks deal with Santaris
SAN DIEGO — Pfizer will pay Danish biotech company Santaris Pharma $14 million for access to its development platform for RNA-based therapies, Pfizer said Tuesday.
The drug maker said the deal would expand on an existing one between Hoersholm, Denmark-based Santaris and Wyeth, which Pfizer acquired in 2009. Santaris could take in up to $600 million in milestone payments, as well as royalties on products developed under the collaboration.
Santaris’ locked nucleic acid, or LNA, platform is designed for the development of RNA-targeted drugs, which Pfizer said could fight diseases in ways that pharmaceuticals and even biotech drugs, such as monoclonal antibodies, cannot.
“The expansion of our collaboration with Santaris Pharma A/S demonstrates our strategic intention to partner with innovative biopharm/biotech companies to explore novel drug design technologies as a potential source for breakthrough therapeutics,” said Mikael Dolsten, Pfizer president for worldwide research and development.
Mylan settles Medicaid reimbursement suit
PITTSBURGH — Generic drug maker Mylan has settled a lawsuit concerning Medicaid reimbursements with the federal government and the state of Texas, Mylan said Dec. 24.
Under the settlement, Mylan will pay $65 million.
Several state attorneys general filed lawsuits against Mylan and other drug companies in September 2003 over Medicaid reimbursements, alleging that the companies defrauded the programs by reporting average wholesale prices greater than the prices of their prescription drugs, thus causing the programs to make excessive payments to healthcare providers.